REFERENCES

1. A. Kondo, (Ed.), in; Microcapsule Processing and Technology, Marcel Dekker, Inc.,

New York, 18, 1979.

2. M.H.Gutcho, (Ed.), in; Microcapsules and Microencapsulation Techniques, Noyes

Data Corporation, New Jersey, 236, 1976.

3. In: Joel Hardman and Lee Limbird, Eds., Goodman and Gilman’s; The Pharmacological

Basis of Therapeutics, 9th

Edn, McGraw-Hill, New york, 1484, 1996.

4. Laurence L.B, John S.L, Keith L.P., Goodman and Gilman’s; The Pharmacological

Basis of Therapeutics, 11th

Edn, McGraw-Hill, New york, 1639-1640, 2006.

5. Ballard, B.E., “An overview of prolonged action drug dosage forms. In: Robinson, J.R.

(Ed). Sustained and controlled release drug delivery systems”, Marcel Dekker, Inc.

New York. pp: 501-528, 1978.

6. Vyas, S. P. and Roop, K. Khar., “Controlled Drug Delivery: Concepts and Advances”,

1st Edition. 258, 2004.

7. Kondo A., Valkenburg, J.W.V., Eds., In; “Microcapsules Processing and Technology”

Marcel Dekker, New York, 32, 1979.

8. Bhalla, H.L. and Menon, M.D., “Long-acting microcapsules of pyrimethamine for

chemoprophylaxis of malaria”, Indian Drugs, 35, 705, 1998.

9. Barik, B.B., Gupta, B.K. and Pal, M., “Preparation and evaluation of rifampicin

microspheres”, Indian J. Pharm. Sci., 59, 110, 1997.

10. Chen, X.M., Ao, B.C. and Xin, J.F., “Medicinal values of neutraceuticals and foods”.,

J. China Pharmacy, 6, 7, 1995.

11. Pitchai Mani, R. and Shirwaikar, A.A., “Sustained-release matrix tablets”, Indian J.

Pharm. Sci., 57, 105, 1995.

12. Nimmannit and Sumanpatra, N., ”Microencapsulation technology and its applications”.,

J. Microencapsul., 13, 643, 1996.

13. Yoncheva, K., Lambov, N. “Development of biodegradable poly (α-methylmalate)

microspheres”, Die Pharmazie, 55, (2), 148-150, 2000.

14. Vachon, M.G. and Nairn, J.G., ”The influence of microencapsulation using Eudragit

RS100 on the hydrolysis kinetics of acetylsalicylic acid”., J. Microencapsul., 14, 281,

1997.

15. Tirkkonen, S., Urtti, A. and Paronen, P., ”The influence of microencapsulation using

Eudragit RS100 on the hydrolysis kinetics of acetylsalicylic acid”., Int. J. Pharm., 124,

219, 1995.

16. Mohsen, A. and Bayomi M., “Aqueous preparation and evaluation of albumin chitosan

microspheres containing Indomethacin”, Drug Dev. Ind. Pharm., 2004, 30(4), 329-339.

17. Kakkar, A.P., “The solubility of nutrients of the substrates and the low degree of

swelling” Eastern Pharmacist, 39, 129, 1996.

18. Chowdhury, S.R., Mukherjee, P.K., Singha, D., Ghosh, L.K. and Pal, M., “Quality

control and standardization of natural products formulation”, Eastern Pharmacist, 38,

137, 1995.

19. Sarry, E.M. and Abdel Zaher, A.O., “Pharmaceutical applications of cyclodextrins”, Bull.

Pharm. Sci., 19, 1, 1996.

20. Rafiee,T. M. and Sadegh, S. N., “Effect of polymers on formulation of controlled release

tablets”., Drug Ind. Pharm., 21, 1193, 1995.

21. An, Z., Lu, G., Mohwald, H. and Li, J., “The molecular level. In this paper we highlight

the recent trends in the electrochemistry of LbL films”, J. Chemistry, 11, 121, 2004.

22. Ichikawa, H., Fukumori, Y. and Moji Adeye, C., “Crosslinked chitosan microspheres for

encapsulation of Diclofenac sodium”, Int. J. Pharm., 156, 39, 1997.

23. Palomo, M.E., Ballesteros, M.P. and Frutos, P., “Diclofenac Sodium Microcapsules: In

Vitro Testing Considerations”, Drug Dev. Ind. Pharm., 23, 273, 1997.

24. Chowdary, K.P.R. and Sastry, V.H., “Microencapsulation of diclofenac”, Eastern

Pharmacist, 40, 119, 1997.

25. Rani, S.H.R., Nargund, L.V. and Prakasam, K., “Formulation and evaluation of

conventional, herbal and novel drug delivery” Indian Drugs, 33, 615, 1996.

26. Khopade, A.J. and Jain, N.K., “Self-assembling nanostructures for sustained ophthalmic

drug delivery”, Pharmazie, 50, 812, 1995.

27. Biju, S.S., Saisivam, S., Rajan, N.S. and Mishra, P.R., “Microencapsulation of

Diclofenac”, Eur. J. Pharm. Biopharm., 58(1), 61, 2004.

28. Akbuga, J. and Bergisadi, N., “Permeation rate of ketoprofen from poloxamer based

bioadhesive”, Drug Dev. Ind. Pharm., 23, 407, 1997.

29. Mandal, M. and Gupta, B.K., “Engineered erythrocytes as a drug delivery system”

Indian J. Pharm. Sci., 59, 181, 1997.

30. Palmieri, G.F., Martell, S., Lauri, D. and Wehrle, P., “Gelatin-acacia complex

coacervation as a method for ketoprofen microencapsulation”, Drug Dev. Ind. Pharm.,

22, 951, 1996.

31. Ricci, M., Blasi, P., Giovagnoli, S., Rossi, S., Macchiarulo, G., Luca, G., Basta, G. and

Calafiore, R., “Solid dispersions of Ketoprofen”., J. Controlled Release, 107(3), 395,

2005.

32. Habib, M.J. and Mesue, R., “Development of controlled release formulations of

ketoprofen for oral use”, Drug Dev. Ind. Pharm., 21, 1463, 1995.

33. Ugwoke, M.I., Verbeke, N. and Kinget, R., “Microencapsulation of apomorphine HCl

with gelatin”. Int. J. Pharm., 148, 23, 1997.

34. Pollock DK, Sheskey PJ., “Micronized ethylcellulose: opportunities in direct-

compression controlled-release tablets”. Pharm Technol. 1996;20:120–130

35. Amperiadou A, Georgarakis M., “Controlled release salbutamol sulphate microcapsules

prepared by emulsion solvent-evaporation technique and study on the release affected

parameters”. Int J Pharm. 1995; 115:1–8.

36. Nagarajan, M., Ganesan, M. and Nalluri, B.N., “Experimental efficacy of targeting PEG-

liposomes encapsulation techniques”, Eastern Pharmacist, 39, 123, 1996.

37. Narisawa, S., Nagata, M., Hirakawa, Y., Kobayashi, M. and Yoshino, H., “Permeability

enhancement of Eudragit RS coating led by physicochemical interactions with organic

acid”, J. Pharm. Sci., 85, 184, 1996.

38. Donbrow, M., Hoffman, A. and Benita, S., “Gradation of microcapsule wall porosity by

deposition of polymer mixtures (Eudragit RL and Eudragit RS)”., J. Microencapsul., 12,

273, 1995.

39. Phuapradit, W., Shah, N.H., Railkar., Williams, L. and Infield, M.H., “In vitro

characterization of polymeric membrane used for controlled release application”. Drug

Dev. Ind. Pharm. 21:955–963. (1995).

40. Badawi, A.A., El-Samaligy, M., Badawi, S.S. and Aziz, R.L., “Controlled release

theophylline delivery systems using Eudragit RS 100”, Pharmazie, 53, 556, 1998.

41. Yao, T., Yamada, M., Yamahara, H. and Yoshida, M., “Tableting of coated particles",

Chem. Pharm. Bull., 46, 826, 1998.

42. Amperiadou, A. and Georgarakis, M., “The emulsion-solvent evaporation technique”,

Drug Dev. Ind. Pharm., 21, 1339, 1995.

43. Valleri, M and Mura, P., “Factors influencing the release of aminophylline from tableted

ethylcellulose microcapsules”, Drug Dev. Ind. Pharm., 21, 2139, 1995.

44. Chowdary, K.P.R. and Girijasankar, G., “Eudragit microcapsules of nifedipine” Drug

Dev. Ind. Pharm., 23, 331, 1997.

45. Antal. I., Zelko, R., Roczey, N., Plachy, J. and Racz, I., “Dissolution and diffuse

reflectance character- istics of coated theophylline particles”. Int. J. Pharm., 55, 83,

1997.

46. Chowdary, K.P.R., Nagarajan, M. and Nalluri, B.N., “Microencapsulation of nifedipine-

MCC solvent deposited system for sustained release”, Indian J. Pharm. Sci., 58, 152,

1996.

47. Yuksel N, Kanık AE, Baykara T. “Comparison of in vitro dissolution profiles by

ANOVA-based model-dependent and independent methods”, Int J Pharm. 2000;

209:57–67.

48. Yuksel, N., Tincer, T. and Baykara, T., “Interaction between nicardipine hydrochloride

for a controlled release system”, Int. J. Pharm., 140, 145, 1996.

49. Gohel, M.C. and Patel, M.M., “Studies in Pellet Preparation and Development of

Modified Release dosage form of Isosorbide Nitrate”, Eastern Pharmacist, 39, 133,

1996.

50. Jayaswal SB, Reddy TSR, Vijay Kumar Gupta. “Preparation and Evaluation of Captopril

microspheres by spherical crystallization”, Indian Drugs. 1995; 32(9):454-57.

51. Kristmundsdottir, T., Gudmundsson, O.S. and Ingvarsdottir, K., “Release of Diltiazem

from. Eudragit microparticles prepared by spray drying”, Int. J. Pharm., 137, 159, 1996.

52. Jones, D.S. and Pearce, K.J., “Investigation of the effects of some process variables on

microencapsulation of propranolol HCl by solvent evaporation method”, Int. J. Pharm.,

118, 199, 1995.

53. Kala, V., Dabre, R., Bhusari, K. P. “A new approach to formulation of lactobacilli used as probiotic

and antidiarrhoa agent”, Indian Drugs. 35, 281-285, 1998.

54. Prakash and Satya., “In-vitro analysis of APA microcapsules for oral delivery of live

bacterial cells”, J Microencapsul., 2005; 22(5):539-547.

55. Samanta K.M., Tamilvanan S., Babu K., Suresh B., “Formulation and Evaluation of

Chlorpromazine Hydrochloride Loaded Self-Cross-Linked Gelatin Microcapsules”,

Indian J. Pharm. Sci., 59. 68, 1997.

56. Dutta, U.K. and Ghosal, S.K., “Targetting drug delivery system”, Indian Drugs, 32, 484,

1995.

57. Ndesendo, V.M.K. and Meixner, W., “Comparison between the Bioadhesivity Potential

of Two Novel Polymer-Based Matrices for Intravaginal Drug Delivery”. J.

Microencapsul., 13, 1, 1996.

58. Shettiger, R. and Damle, A.V., “Controlled release pellets of isoxsuprine hydrochloride”

.Indian J. Pharm. Sci., 57, 210, 1995.

59. Tang, H. Q., Jiang, W. L., Zhao, G.H. and Zou, L. J. “Traditional Chinese Medicine” ,

Chinese J. Pharm., 27, 11, 1996.

60. Tuncel, T., Bergisadi, N., Akin, L., Otuk, G. and Kuscu, I., “ In vitro and. In vivo studies

on microcapsules and tabletted microcapsules of cephradine”, Pharmazie, 51, 168, 1996.

61. Kondo, T., Hafez, E., Abdel-Monem, H., EI-Harras, S. and EI-Gibaly, I. et al.,

“Characterization of Piroxicam-cyclodextrins Inclusion”, Pharmazeutische Industrie,

58, 552, 1996.

62. Tomoaki, Y., Machida, Y., Hiraku, O. and Nagai, T., “Development and characterization

of rifampicin loaded floating microspheres”. Drug Dev. Ind. Pharm., 29, 417, 2003.

63. Stevens, W.F, “Chitosan-alginate multilayer beads for gastric passage and controlled

intestinal release of protein”, Drug Dev. Ind.Pharm.2003, 29, 713-724.

64. Zhao, Y., Chen, W., Cai, Q., Wang, S., Bo. J. and Wu, C., “Erosion Induced Controllable

Release of Gliclazide Encapsulated Inside Degradable Polymeric Particles”, Macromol.

Biosci., 4(3), 308, 2004.

65. Asrar, J., Ding, Y., La Monica, R.E. and Ness, L.C., “Controlled release of tebuconazole

from a polymer matrix microparticle: release kinetics and length of efficacy”. J. Agric.

Food Chem., 52(15), 4814, 2004.

66. Portero, A., Remunan-Lopez, C., Criado, M.T. and Alonso, M. J., “Preparation of

reacetylated chitosan microspheres with suitable properties for the controlled release of

active anti-microbial agents, such as amoxycillin and metronidazole, in the gastric

cavity”. J. Microencapsul., 19(6), 797, 2002.

67. Mandal, T.K., Bostanian, L.A., Graves, R.A., Chapman, S.R. and Womack, “A

biodegradable, orally active controlled-release formulation of amifostine”, Drug Dev.

Ind. Pharm., 28(3), 339, 2002.

68. Ozalp, Y., Ozdemir, N., Kocagoz, S. and Hasirci, V., “Controlled release of vancomycin

from biodegradable microcapsules”. J. Microencapsul., 18(1), 89, 2001.

69. Nettey H., Haswani D., D’Souza M., Oettinger C. “In-vitro anti-microbial effect of encapsulated

vancomycin on internalized Staph. Aureus within endothelial cells”. Drug Development and

Industrial Pharmacy, 33 (2): 133-9, 2007.

70. Hombreio-Perez, M., Siepmonn, J., Zinuti, C., Lamprecht, A., Ubrich, N., Hoftman, M.,

Bodmeier, and Maincent, P., “Non-degradable microparticles containing a hydrophilic or

a lipophilic drug: preparation, characterization and drug release modeling”, J. Controlled

Release, 88, 413, 2003.

71. Kevin A., Jones, M.P., Fresneau, A.M., Angels, F. and Maria, J.A., “Chitosan

nanoparticles as delivery systems for doxorubicin”, J. Controlled Release, 73, 255, 2001.

72. Dinesh B. Shenoy, Reshma J. D’Souza, Sandip B. Tiwari and N. Udupa., 2003. “Potential

application of polymeric microsphere suspension as subcutaneous depot for insulin”, Drug

Dev. Ind. Pharm., 29(5), 555-563

73. Agnihotri, S.A. and Aminabhavi, T.M., “Recent advances on Chitosan based micro and nano

particles in drug delivery”, J. Controlled Release, 28, 245, 2004.

74. Shi, X.Y. and Ton, T.W., “Preparation of chitosan/ethylcellulose complex of vitamin D2”,

Biomaterials, 23 (23), 4469, 2002.

75. Obeidat, W.M. and Price, J.C., “Theophylline microspheres were prepared by the emulsion-

solvent evaporation method using cellulose acetate butyrate (CAB381-20) and mixtures of

CAB381-20(R) and cellulose acetate phthalate”., J. Microencapsul., 21, 47, 2004.

76. Song, M., Li, N., Sun, S., Tiedt, L.R., Liebenberg, W. and de Villiers, M.M., “Microcapsules

prepared by emulsion solvent evaporation”, Farmaco., 60(3), 261, 2005.

77. Savolainen, M., Herder, J., Khoo, C., Lorgvist, K., Dahigvist, C., Glad, H. and Juppo, A.M.,

“Controlled-release tablets of poorly-soluble drug felodipine”., Int. J. Pharm., 27, 47, 2003.

78. Assimopoulou, A.N. and Papageorgiou, V.P., “Preparation and release studies of alkannin-

containing microcapsules”, J. Microencapsul., 21(2), 161, 2004.

79. Pedersen, J.L., Lilleso, J., Hammer, N.A., Werner, M.U., Holte, K., Lacouture, P.G. and Kehlet,

H., “Bupivacaine in microcapsules prolongs analgesia after subcutaneous”, J. Anesth. Analg.,

99, 912, 2004.

80. Wang, H. J., Li, X.R., Huang, Y.Q., Zhang, Y.L., Hu, X. and Liu, Y., “Invivo and Invitro

Pharmaceutical behavior of lycopene microcapsules”.,Yao Xue Xue Bao., 40(9), 787, 2005.

81. Pargaonkar, N., Lvov, Y.M., Li, N., Steenekamp, J.H. and de Villiers, M.M., “Controlled release

of dexamethasone from microcapsules”, Pharm. Res., 22(5), 826, 2005.

82. Mukherjee, B., Mahanti, B., Panda, P. and Mahapatra, S., “Preparation and evaluation of

verapamil hydrochloride microcapsules”, American J. Therapeutics, 12(5), 417, 2005.

83. Yasmeen, R., Shoaib, M.H. and Khalid, H., “Comparative Study of Different Formulations of.

Atenolol”, Pak. J. Pharm. Sci., 18, 47, 2005.

84. Rao, K.R., Senapati, P.and Das, M.K., “Formulation and in vitro evaluation of ethyl cellulose

microspheres containing zidovudine”, J. Microencapsul., 22, 863, 2005.

85. Budhian, A., Siegel, S.J. and Winey, K.I., “Production of haloperidol-loaded PLGA nanoparticles

for extended controlled drug release of haloperidol”, J. Microencapsul., 22, 773, 2005.

86. Persyn, J.T., McDonough, J. A., Nino, J. A., Dixon, H. and Boland, E.J., “Use of

microencapsulation technology in combination with absorption”, J. Microencapsul., 22, 737,

2005.

87. Yuan, X.J., Zhang, Z.R., Song, Q.G. and He, Q., “Mucosal delivery of cytotoxic therapeutic

agents: response of rat nasal mucosa to microencapsulated ethopropazine HCl enantiome”,

Arch. Pharm. Res., 29, 795, 2006.

88. Yang, G.M., Kuo, J.F. and Woo, E.M., “Preparation and control-release kinetics of isosorbide

dinitrate microspheres”. J. Microencapsul., 23, 622, 2006.

89. Govender, S., Lutchman, D., Pillay, V., Chetty, D.J. and Govender, T., “Enhancing drug

incorporation into tetracycline-loaded chitosan microspheres for periodontal therapy”,

Microencapsul., 23, 750, 2006.

90. Das, M.K. and Rao, K.R., “Microencapsulation of Zidovudine by double emulsion solvent

evaporation method”., Acta. Pol. Pharm., 63, 141, 2006.

91. Homar, M., Ubrich, N. E., Ghazouani, F., Kristl, J., Kerc, J. and Maincent, P., “Influence of

polymers on the bioavailability of microencapsulated celecoxib” J. Microencapsul, 24, 621,

2007.

92. Schaffazick, S.R., Pohlmann, A.R.and Guterres, S.S., “Nanocapsules, nanoemulsion and

nanodispersion containing melatonin: preparation, characterization and stability

evaluation”, Pharmazie, 62, 354, 2007.

93. Jackson, J.K., Hung, T., Letchford, K. and Burt, H.M., 13. “The characterization of paclitaxel-

loaded microspheres manufactured from blends of poly (lactic-co-glycolic acid) (PLGA) and

low molecular weight diblock copolymers”, Int. J. Pharm., 342, 6, 2007.

94. Kar, M. and Choudhury, P.K., “Formulation and evaluation of ethyl cellulose microspheres

prepared by the multiple emulsion technique” Pharmazie, 62, 122, 2007.

95. Giovagnoli, S., Blasi, P., Schoubben, A., Rossi, C. and Ricci, M., “Preparation of large porous

biodegradable microspheres by using a simple double-emulsion method for capreomycin

sulfate pulmonary delivery”, Int. J. Pharm., 333 (2007), pp. 103–111

96. Jaspart, S., Bertholet, P., Piel, G., Dogne, J.M., Delattre, L. and Evrard, B., “Pulmonary drug

delivery”, Eur. J. Pharm. Biopharm., 65, 47, 2007.

97. Gal, A. and Nussinovitch. A., “Hydrocolloid carriers with filler inclusion for diltiazem

hydrochloride release”, J. Pharm. Sci., 96, 168, 2007.

98. Amitava, G., Uday Kumar, N., Prasant, R., Tanusree, N. and Partha, R., “Preparation and

Evaluation and invitro-invivo correlation (IVIVC) study of lamivudine loaded microspears”.,

Research J. Pharm. and Tech., 1(4), 353, 2008.

99. Rajinikanth, P. S., Karunagaran, L. N., Balasubramaniam, J. and Mishra,“ Formulation and

evaluation of clarithromycin microspears for eradication of H.Pylori”., Chem. Pharm. Bull.,

56(12), 1658, 2008.

100. Bhabani Shankar, N., Uday kumar, N., Balakrishna, K. P. and Prasant kumar, R.,

“Design and Evaluation of Controlled Release Bhara Gum Microcapsules of

Famotidine for Oral Use”, Research J. Pharm. and Tech., 1(4), 433, 2008.

101. Sah, H., Toddywala, R. and Chien, Y.W., “Continuous release of proteins from biodegradable

microcapsules and in vivo evaluation”, J. Controlled Release, 35, 137, 1995.

102. Uchida, T., Shiosaki, K., Nukada, Y., Fukada, K. and Matsuyama, K. et al., “Microencapsulation

of hepatitis B core antigen for vaccine preparation”, Pharma. Res., 15, 1708, 1998.

103. Haque, T., Chen, H., Ouyang, W., Martoni, C., Lawuyi, B., Urbanska, A.M. and Prakash,

S.,”Advances in Regenerative Medicine: Role of Nanotechnology, and Engineering”,

Biotechnol. Lett., 27(5), 317, 2005.

104. Bittner, B., Morlock, M., Koll, H., Winter, G. and Kissel, T., “Recombinant human

erythropoietin (rhEPO) loaded poly (lactide-co-glycolide) microspheres: influence of the

encapsulation technique and polymer purity on microsphere characteristics”, Eur. J. Pharm.

Biopharm., 45, 295, 1998.

105. Pean, J.M., Venier-Julienne, M.C., Boury, F., Menei, P. and Benoit, J.P. et. al., “NGF release

from poly (-lactide-co-glycolide) microspheres”, J. Controlled Release, 56, 175, 1998.

106. Cleland JL, Jones AJ. “Stable formulations of recombinant human growth hormone and

interferon-gamma for microencapsulation in biodegradable microspheres”. Pharm Res 1996;

13:1464–75.

107. Hermann, J. and Bodmeier, R., “The effect of particle microstructure on the somatostatin

release from poly (lactide) microspheres”, Int. J. Pharm., 126, 129, 1998.

108. Kovacs-Nolan, J. and Mine, Y., “Microencapsulation for the gastric passage and controlled

intestinal release of immunoglobulin”, J. Immunological. Methods, 296(1-2), 199, 2005.

109. Thomas, T.T., Kohane, D.S., Wang, A. and Langer, R., “Microparticulate formulations for the

controlled release of interleukin-2”, J. Pharm. Sci., 93 (5), 1100, 2004.

110. Holland, T.A., Tabata, Y. and Mikos, A.G., “In vitro release of transforming growth factor-beta

1 from gelatin microparticles encapsulated in biodegradable, injectable oligo(poly(ethylene

glycol) fumarate) hydrogels”., J. Controlled Release, 91(3), 299, 2003.

111. Takada, S., Yamagata, Y., Misaki, M., Taira, K. and Kurokawa, T., “Controlled-release

formulations of recombinant human growth hormone (rhGH)”, J. Controlled Release, 88(2),

229, 2003.

112. Singh, M., Singh, O. and Talwar, G.P., “Biodegradable delivery system for a birth control

vaccine”, Pharm. Res., 12, 1796, 1995.

113. Azarnia, S., Lee, B.H., Robert, N. and Champagne, C.P., “Microencapsulation of a recombinant

aminopeptidase (PepN) from Lactobacillus”, J. Microencapsul., 25, 46, 2008.

114. Badkar, A.V., Smith, A.M., Eppstein, J.A.and Banga, A.K., “Delivery of Insulin Using

Microneedles In-Vivo”, Pharm. Res., 24, 1389, 2007.

115. Ho, J., Wang, H. and Forde, G. M., “Process considerations related to the microencapsulation

of plasmid DNA via ultrasonic atomization”, Biotechnol. Bioengg., 101(1), 172, 2008.

116. Nkansah, M. K., Tzeng, S. Y., Holdt, D. T. and Lavik, E. B., “Poly (lactic-co-glycolic acid)

nanospheres and microspheres”., Biotechnol. Bioengg., 100(5), 1010 , 2008.

117. Saravanakumar, A., Sunita, M., Madulika, P., Pavani, S., Chandu, A. N., Umesh, M.,

Kamalakannan, K. and Sivakumar, T., “Polylactic Acid Microspheres as A Potential Vaccine

Delivery System for the Tetanus Toxoid: Preparation and In Vitro Dissolution Study”. Research

J. Pharm. and Tech., 1(4), 453, 2008.

118. Jiang, W. and Schwendeman, S. P., “Stabilization of tetanus toxoid encapsulated in PLGA

microspheres”, Mol. Pharm., 5(5), 808, 2008.

119. Dorle, A.K. and Pathak, Y.V., “Effect of pH on the release characteristics of drugs”, Drug Dev.

Ind. Pharm., 14, 2557, 1998.

120. Dorle, A.K., ’Effect of hydrophobic binding on microencapsulating materials”, Indian J. Pharm.

Sci., 54, 10, 1992.

121. Chowdary, K.P.R. and Vijaya Ratna, J., Chowdary, K.P.R. and Vijaya Ratna, “Preparation and

evaluation of cellulose acetate microcapsules of theophylline”, Indian J. Pharm. Sci., 52, 279,

1990.

122. Chowdary, K.P.R. and Vijaya Ratna, J.,”Studies on micro encapsulation by cellulose acetate”,

Indian Drugs, 28, 361, 1991.

123. Chowdary, K.P.R. and Vijaya Ratna, J., “Preparation and evaluation of cellulose acetate

Diclofenac Microspheres”, Indian Drugs, 29, 494, 1992.

124. Chowdary K.P.R. and Ramesh, K.V.R.N.S., “Solid dispersion of nifedipine in combined carriers,

PVP-MCC and HPC-MCC”, Drug Dev. Ind. Pharm., 21, 1183, 1995.

125. El-Fahan, T.H. and Massoud, A.A., “Nanocapsules as carrier for oral peptide delivery”, J.

Controlled Release, 32, 279, 1994.

126. Gutierrez-Pauls, L., Gonzalez-Alvarez, I., Lareo, Barone, M., Gil-Alegre, M. E. And Torres-

Suarez, A.I., “Poly (epsilon-caprolactone) microparticles formed by the the emulsion-

evaporation method”, Pharmazie, 62, 864, 2007.

127. Vlugt-Wensink, K.D., de Vrueh, R., Gresnigt, M.G., Hoogerbrugge, C.M., van Buul-Offers, S.C.,

de Leede, L.G., Sterkman, L.G., Crommelin, D.J., Hennink, W.E. and Verrijk, R., “hGH dextran

microsphere formulation”, Pharm. Res., 24, 2239, 2007.

128. Schuidt, U. and Hunkeler, D., “Microencapsulation Techniques”, J. Microencapsul., 24, 1,

2007.

129. Kar, M. and Choudhury, “Formulation and evaluation of ethyl cellulose microspheres

prepared by the multiple emulsion techniques”, P.K., Pharmazie, 62, 122, 2007.

130. Berchane, N.S., Jebrail, F.F., Carson, K.H., Rice Ficht, A.C. and Andrews, M.J., “Diameter and

size distribution of PLG Microspears”., J. Microencapsul., 23, 539, 2006.

131. McCarron, P.A., Donnelly, R.F. and Marouf, W., “Celecoxib-loaded poly (D, L-lactide-co-

glycolide) nanoparticles prepared using a novel and controllable combination of diffusion and

emulsification steps as part of the salting-out procedure”. J. Microencapsul., 23, 480, 2006.

132. Singh, B.N.and Kim, K.H., “Effects of divalent cations on drug encapsulation efficiency of

deacylated gellan gum”, J. Microencapsul., 22, 761, 2005.

133. Chowdary, K.P.R., Mohapatra, P. and Murali Krishna, M.N., “Evaluation of olibanum resin as

microencapsulating agent for controlled drug delivery”, Indian J. Pharm. Sci., 68, 497, 2006.

134. Chowdary, K.P.R. and Mohapatra, P., “Pharmacokinetic Evaluation of Natural Resin Coated

Microcapsule”, International J. Chemical Sciences, 4, 747, 2006.

135. Panos, I., Acosta, N. and Heras, A., “New drug delivery systems based on chitosan”, Curr. Drug

Discov. Technol., 5(4), 333, 2008.

136. Tamilvanan, S. and Sa, B., “Effect of production variables on the physical characteristics of

ibuprofen-loaded polystyrene microparticles”, PDA J. Pharm. Sci. Technol., 62(3), 177, 2008.

137. Singh, P., Desai, S. J., Simonelli, A. P. and Higuchi, W. I., “Role of wetting on the rate of drug

release from inert matrices”, J. Pharm. Sci., 57 (2), 217, 1968.

138. Nakagami, H., Keshikawa, T., Matsumura, M. and Tsukamoto, H., “Application of aqueous

suspen- sions and latex dispersions of water-insoluble polymers for tablet and granule

coatings”, Chem. Pharm. Bull., 39 (7), 1837, 1991.

139. Donbrow, M. and Friedman, M.,”Enhancement of Permeability of Ethyl Cellulose Films for

Drug Penetration”, J. Pharm. Pharmac., 27, 633, 1975.

140. Efentakis, M., Al-Hmoud, H., Buckton, G. and Rajan, Z., “The influence of surfactants on drug

release from hydrophobic matrix”., Int. J. Pharm., 70, 153, 1991.

141. Reaven, G.M., “The most recent National Health and Nutrition Examination Survey hormone in

older hypothyroid patients”, American J. Med., 75, 8, 1983.

142. Felinglos, M.N. and Lebovitz, H.E., “Safety and efficacy of glipizide”, American J. Med., 75, 60,

1983.

143. Lebovitz, H.E., “Clinical utility of oral hypoglycemic agents in the management of patients with

noninsulindependent diabetes mellitus”., American J. Med., 75, 94, 1983.

144. Kennedy, D.L., Piper, J.M. and Baum, C., “Trends in the use of oral hypoglycemic agents”,

Diabetes Care, 11, 558, 1988.

145. Gerich, J.E., “Oral hypoglycemic agents”, New England J. Med., 321, 1231, 1989.

146. Wahlin-Boll, E., Almer, L.O. and Melander, A., “Bioavailability, pharmacokinetics and effects of

glipizide in type 2 diabetics”, Clin. Pharmacokinetics, 7, 363, 1982.

147. Feldman, J.M. Glyburide: “A second generation sulfonylurea hypoglycemic agent”,

Pharmacotherapy, 5, 43, 1985.

148. Jaspan, J.B., Metabolism, “Effects of sorbinil therapy in diabetic”, 9; 149(46):3111-4, 1987.

149. Drentz, A.J., Ferner, R.E. and Bailey, C.J., “Comparative tolerability profiles of oral antidiabetic

agents”, Drug Safety, 11, 223-241, 1994.

150. Melander, A. and Wahlin-Boll, E., “Clinical pharmacology of glipizide”, American J. Med., 75, 41,

1983.

151. Lebovitz, H.E., “Glipizide: A second generation sulfonylurea hypoglycemic agent”

Pharmacotherapy, 5, 63, 1985.

152. Groop, L., Wahlin-Boll, E., Groop. P.H., Soterman, K.J., Melander, A., Tolppaner, E.M. and

Fyhrquist, F., Pharmacokinetics and metabolic effects of glibenclamide and glipizide in type 2

diabetics, Eur. J. Clin. Pharmacol., 28, 697, 1985.

153. Ahren, B., Lundquist, I. And Schersten, B., “Effects of glipizide on various consecutive insulin

secretory stimulations in patients with type 2 diabetes”, Diabetes Research, 3, 293, 1986.

154. Melander, A., “Clinical pharmacology of sulfonylureas”, Metabolism, 38, 12, 1987.

155. Groop, P.H., Melander, A. and Groop, L.C., “The acute effect of preprandial exogenous and

endogenous sulphonylurea-stimulated insulin secretion on postprandial glucose excursions in

patients with type 2 diabetes”, Diabet. Med., 10, 633, 1993.

156. Eisen, S.A., Miller, D.K., Woodward, R.S., Spitznazel, E. and Przybeck, T.R., “The effect of

prescribed daily dose frequency on patient medication compliance”, Arch. Internal Med.,

150(9):1881-4., 1990.

157. Botelho, R.J. and Dudrak, R.I.I., “Home assessment of adherence to long-term medicines in the

elderly”, J. Family Practice, 35, 61, 1992.

158. Pyorala, K., Unitupa, M., Laakso, M., Sitonen, O., Niskanen, L. and Ronnema, T., “Diabetes and

atherosclerosis: an epidemiologic view”, Diabetes Metabolism, 13, 345, 2000.

159. Stout, R.W., “Insulin and atheroma. 20-yr perspective”. Diabetes Care, 13, 631, 1990.

160. Font Bonne, A.M. and Eschwege, E.M.,”Insulin and cardiovascular disease. Paris Prospective

Study”, Diabetes Care, 14, 461, 1991.

161. Okhubu, Y., Kishikawa, H., Araki, E., Miyata, T., Isami, S., Motoyoshi, S., Kojima, Y., Furuyoshi, N.

and Shichiri, M., “Intensive insulin therapy prevents the progression of diabetic microvascular

complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized

prospective 6-year study”. Diabetes Res. Clin. Practice, 28, 103, 1995.

162. Berelowitz, M., Fischtte, C.T., Cefalu, W., Schade, D.S., Sutfin, T. and Kourides, I.A., “Comparative

efficacy of a once-daily controlled-release formulation of glipizide and immediate-release

glipizide in patients with NIDDM”, Diabetes Care, 17, 1460-64, 1994.

163. Berelowitz, M., Fischtte, C.T., Cefalu, W., Schade, D.S., Sutfin, T. and Kourides, I.A., “Comparative

efficacy of a once-daily controlled-release formulation of glipizide and immediate-release

glipizide in patients with NIDDM”, Diabetes Care, 17, 1460-64, 1994.

164. Simonson, D.C., Feinglos, M. and Shamon, H., “The Glipizide Gastrointestinal Therapeutic System

Study”, Diabetes Care, 20(4), 597, 1997.

165. Cefalu, W.T., Bell-Farrow, A.D., Wang, Z.Q., MC Bridge, D., Dalgleish, D. and Terry, T.G., “Effect

of glipizide GITS on insulin sensitivity, glycemic indices, and abdominal fat composition in

NIDDM”, Drug Development Research, 44, 1-7, 1998.

166. Physician Desk Reference (PDR), product information, Pfizer Inc., 54th Edn., Medical Economics

Company, 2000, 2008.

167. Foster, R.H. and Polsker, G.L., “A review of the pharmacoeconomic implications of the extended-

release formulation in type 2 diabetes mellitus”. Pharmacoeconomics, 18(3), 289, 2000.

168. Thombre, A.G., Denoto, A.R. and Gibbes, D.C., “Delivery of glipizide from asymmetric membrane

capsules using encapsulated excipients”, J. Controlled Release, 60, 333, 1999.

169. Garcia, J. and Ghaly, E.S., “Evaluation of bioadhesive glipizide spheres”., Pharm. Dev. And Tech.,

6, 407, 2001.

170. Verma, R.K. and Garg, S., “Development and evaluation of osmotically controlled oral drug

delivery system of glipizide”, Eur. J. Pharm. Biopharm., 57, 513, 2004.

171. Gan, Y., Pan, W., Wei, M. and Zhang, R., “Cyclodextrin complex osmotic tablet for glipizide

delivery”., Drug Dev. Ind. Pharm., 28, 1015, 2002.

172. Garcia. J. and Ghaly, E.S., “Evaluation of bioadhesive glipizide spheres and compacts from

spheres”, PR. Health Sci. J., 20(1), 25, 2001.

173. Chowdary, K.P.R. and Rao, Y.S., “Design and in vitro and in vivo evaluation of mucoadhesive

microcapsules of glipizide for oral controlled Release”., AAPS Pharm. Sci. Tech., 4(3), 320, 2003.

174. Dhawan, S., Singh, B., Garg, S.K., Hota, D., Dash, R.J., Singla, A.K. and Sinha, V.R., “Bioavailability

of immediate and Extend release formulations of glipizide in healthy male volunteer”, Clin.

Pharmacokinetics, 45(3), 317, 2006.

175. Sweetman, C.S., “Martindale the complete drug reference”, London, Pharmaceutical Press, 333,

2002.

176. Tripathi, K.D., “Essential of medical pharmacology”, New Delhi, Jaypee brother’s medical

publishers (p) ltd., 247-51, 2003.

177. Tan, M.H., Johns, D., Strand, J., Halse, J., Madsbad, S. and Eriksson, J.W., et al., “Sustained effect

of pioglitazone vs. glibenclamide on insulin sensitivity, glycemic control and lipid profile in

patient with type II diabetes”, Diabet Med., 21, 859 -866, 2004.

178. Anant, A., Rahul, T., Pandey, M. and Saraf, A.S., IPCA, 2009.

179. Wong, H., Ozalp, Y., Lainesse, A. and Alpan, R.S., “In vivo bioequivalence of oral antidiabetic

agents: pioglitazone tablets”, Arzneimittel-Forschung, 54(9A), 618-624, 2004.

180. Nagalakshmi, S. and Abdul Hasan Sathali, ”Sustained effect of pioglitazone Vs glibenclamide on

insulin sensitivity ,glycemic control and lipid profile in patients with type 2 diabetis” , The Indian

Pharmacist, New Delhi, 8, 57-66, 2009.

181. Singh, C., Jain, KA., Kumar, C., and Agarwal, K., “Design and invitro evaluation of mucoadhesive

microspheres of pioglitazone”, J. Young Pharma., 1(3), 195-198, 2009.

182. Wagner, J., Correlation of in vivo with in vitro data. Theoretical and practical

considerations., Deug. Intell. Clin.Pharm; 4: 32, 1970.

183. Noyes, A. A., and Whitney, W. R., The rate of solution of solid substances in their own

solutions. J. Ame. Chem. Soc; 19: 930., 1897.

184. Higuchi, W. I., Nir, N. A., and Desai, S. J., Dissolution-modulating mechanism of pH

modifiers in solid dispersion containing weakly acidic or basic drugs with poor water

solubility J. Pharm. Sci; 54: 1405., 1965.

185. Higuchi, T., and Ikeda, M., Letter: Rapidly dissolving forms of digoxin: hydroquinone

complex, J. Pharm. Sci, 63: 809, 1974.

186. Zogolio, M. A., Maulding, H. V., and Windheuser, J., Complexes of ergot alkaloids and

derivatives. I. The interaction of caffeine with ergotamine tartrate in aqueous solution, J.

Pharma. Sci; 1969, 58: 222.

187. Mullins, J. D., and Macek, T. J., Pharmaceutical applications of Polymorphism, J. Amer.

Pharm. Assoc; 1958, 47: 297.

188. Aguiar, A. J., Krc, J., Kinkel, A. W., and Samyn, J. C., Effect of Polymorphism on the

Absorption of Chloramphenicol from Chloramphenicol Palmitate, J. Pharm. Sci; 1967,

56: 847.

189. Moustafan, M. A., Khalil, S. A., Ebian, A. R., and Motawi, M. M., Preparation,

characterization, and interconversion of different crystal forms., J. Pharm. Sci; 1974,

63:1103.

190. Moustafan, M. A., Khalil, S. A., Ebian, A. R., and Motawi, M. M., Succinylsulfathiazole

crystal forms : Preparation, characterization, and interconversion of different crystal

forms.J. Pharm. Sci; 1975, 64:1481.

191. Hazratwala, B. R., and Taylor, B., dissolution studies on different dosage forms, J.

Pharma. Pharmacol; 1974, 28: 934.

192. Goyal, V. C., Kohil, D. V., and Upadhyay, R. K., Enhancement of solubility and

dissolution., Indian Drugs; 1982, 19: 233.

193. Sanghvi, N. M., and Jirani, N. J., A system for enhancing the water dissolution rate and

solubility of poorly soluble drugs. Indian Drugs; 1982, 19: 421.

194. Chiou, W. L., Chen, S. J., and Athanikar, N., Enhancement of dissolution rates of poorly

solubule drugs., J. Pharm. Sci; 1976, 65: 1702.

195. Poole, J. W., Own, G., Silvero, J., Freyhot, J. N., and Roseman, S. B., The absorption of

the anhydrous and trihydrate forms of ampicillin., Curr. Ther. Res; 1968, 10: 292.

196. Shefter, E., and Higuchi, T., Dissolution behavior of crystalline solvated, J. Pharm.

Assoc; 1958, 47: 297.

197. Leonard, J. R., The influence of solubility on the rate of gastrointestinal absorption of

aspirin, Clin. Pharmacol. Ther; 1963, 4: 476.

198. Truitt, E. B., and Morgan, A. M., Gastrointestinal factors in aspirin absorption. A

quantitative study. J. Pharm. Sci; 1964, 53: 129.

199. Javid, K. A., and Eadwallachr, D. E., Dissolution of aspirin from tablets containing

various buffering agents, J. Pharm. Sci; 1972, 61: 1370.

200. Nelson, E., Comparative dissolution rates of weak acid and their sodium salts, J. Pharm.

Sci; 1958, 47: 300.

201. Chowdary, K. P. R., and Srirama Murthy, A., Preparation and Evaluation of Glyceryl

Monostearate Microcapsules of Nitrofurantoin, 22; issue 525; Indian Drugs; 1985.

202. Wan, S. H., Pentikainen, P. J., and Azarnoff, D. L., Bioavailability of aminosalicylic acid

and its various salts in humans., J. Pharm. Sci; 1974, 63:708.

203. Nelson, E., Knoechel, E. L., Hamlin, W. E., and Wagner, J. G., Influence of the

absorption rate of tolbutamide., J. Pharm. Sci; 1962, 51: 509.

204. Nelson, E., Influence of dissolution rate and surface area on tetra- cycline absorption., J.

Amer. Pharm. Assoc. Sci. Ed; 1959, 48: 96.

205. Juncher, H., and Raschov, F., The solubility of oral preparations of penicillin-V.,

Antibiot. Med. Clin. Ther; 1957, 4: 497.

206. Nelson, E., Comparative dissolution rates of weak acids and their sodium salts, J. Amer.

Pharm. Assoc. Sci. Ed; 1958, 47: 297.

207. Vivino, E. A., Drugs solubility and rate, J. Phsrm.Sci; 1954, 43: 234.

208. Gagliani De Graff, A.C., and Kupperman, H.S., Enhanced theophylline blood levels

obtained after ingestion of choline theophyllinate as compared to aminophylline with or

without aluminum hydroxide Int. Rec. Med. Gen. Prac. Clin; 1954, 167: 251.

209. Daehne, W. V., Frederiksen, E., Gundersen, E., Lund, F., Morch, P., Peterson, H.J.,

Roholt, K., Tybring, L., and Godtfredsen, W. O., Acyloxymethyl esters of ampicillin., J.

Med. Chem; 1970, 13: 607.

210. Schwartz, M. A., and Hayton, W. L., Relative Stability of Hetacillin and Ampicillin in

Solution, J. Pharm. Sci; 1972, 61: 906.

211. Sinkula, A. A., Rationale for design of acid ester by the neighbouring dextran hydroxy

groups, Acta. Pharm. Suec; 1976, 7(13 Suppl)

212. Butter, K., English, A. R., Knirsch, A. K., and Korst, J. J.,Metabolism and laboratory

studies with indanyl carbenicillin., Del. Med. J; 1971, 43: 366.

213. Sinkula, A. A., and Lewis, C., Clinically useful antibiotics obtained by directed chemical

modification-lincomycins., J .Pharma. Sci; 1973, 62: 1757.

214. Bedford, C., Busfield, D., Child, K. J., Mac Gregor, J., Sutherland, P., and Tomich, E. G.,

Studies on the biological disposition of griseofulvin, an oral antifungal agent., Arch.

Dermantol; 1960, 81: 735.

215. Atkinson, R., Bedford, C., Child, K. J., and Tomich, E.G., Effect of Particle Size on

Blood Griseofulvin-Levels in Man., Nature (Lond.); 1962, 193: 588.

216. Shaw, T. R. D., and Careless, J. E., The effect of particle size on the absorption of

digoxin., Eur. J. Clin. Pharmacol; 1974, 7: 269.

217. Jounela, A. j., Pentikainen, P. J., and Sothmann, A., Effect of particle size on the

bioavailability of digoxin. Eur. J. Clin; 1975, 8; 365.

218. Finholt, P., Dissolution Technology (Leeson L J. and Carstensen J t. Eds) ., Academy of

Pharmaceutical Association Washington D C; 1974, p. 106-146.

219. Reinhold, J. G., Phillips, F. J., and Flippin, H. F., A comparison of the behavior of

microcrystalline sulfadiazine with that of ordinary. Amer. J. Med. Sci; 1945, 210: 141.

220. Finholt, P., and Solvang, S., Dissolution kinetics of drugs in human gastric juice: the role

of surface tension. J. Pharma.Sci; 1968, 57: 1322.

221. Newton, J., Rowley, G., and Tornblom, J., ketoprofe Invivo and Invitro absorption

Studies, J. Pharm. Pharmacol; 1971, 23: 1565.

222. Kakemi, K., Arita, T., and Muranishi, S., Absorption and excretion of drugs, Chem.

Pharm. Bull; 1965, 13: 976.

223. Jain, S. C., and Agrawal, G. P., Pharmacodynamic drug interaction of mexiletine with

tolbutamide in rats, Indian. Drugs; 1981, 19: 108.

224. Narurkar, A. N., and Jarowski, C. I.,Dissolution studies of Prednisolone., Drug Dev. Ind.

Pharm; 1983, 9: 999.

225. Mortada, L. M., and Mortada, S. A. M., Dissolution Studies of Sustained Release

Metformin Tablet., Acta. Pharm. Tech; 1982, 28: 297.

226. Monkhouse, D. C., and Lach, J. L., Use of adsorbents in enhancement of drug

dissolution. J. Pharm. Sci; 1972, 61: 1430.

227. Johansen, H., and Moller, N., Studies on microcrystalline cellulose. Arch Pharm Chem

Sci Ed; 1976, 4: 114.

228. Johanson, H., and Moller, N., Surface area stability of micronized steroids, Arch. Pharm.

Chem. Sci. Ed; 1977, 5: 171.

229. Mayersohn, M., and Gibaldi, M., New method of solid-state dispersion for increasing

dissolution rates, J. Pharm. Sci; 1966, 55: 1323.

230. Stupak, E. I., and Bates, T. R., dissolution of reserpine–polyvinylpyrrolidone

coprecipitates J. Pharm. Sci; 1972, 61: 400.

231. Kaur, R., Grant, D .J. W., and Eaves, T., Enhancement of dissolution rate of valdecoxib

by solid dispersions, J. Pharm. Sci; 1980, 69: 1317.

232. Sekiguchi, K., Obi, N., and Ueda, Y., Enhancement of Oral Bioavailability and Solid

Dispersion: A Review., Chem. Pharm. Bull; 1964, 12; 134.

233. The Biopharmaceutics classification system (BCS) guidance, Center for Drug Evaluation

and Research, US Food and Drug Administration; 2001, http://www.fda.gov/cder.

234. Loftsson T, Brewster ME., “Drug solublization and stabilization” J. Pharm. Science., 85:

1024-1074, 1996.

235. Loftsson T, Brewter ME., “Cyclodextrin as Pharmaceutical Excipients”. Pharma

Manager; 5, 22-31., 1997.

236. Szejtli, J., “Medicinal applications of cyclodextrins” Med. Res. Rev., 14, 353-386., 1994.

237. Bekers O, Uijtendaal EV, Beijnen JH, Bult A, Underberg WJM: “Cyclodextrins in the

pharmaceutical field”. Drug Dev. Ind. Pharm. 17, 1503-1549., 1991.

238. Loftsson T, Brewster ME, “Pharmaceutical applications of cyclodextrins and Drug

solubilization and stabilization”., J. Pharm. Sci., 85(10): 1017-1025., 1996.

239. Szejtli, J., Akademiai, Kiado., “Cyclodextrins and their Inclusion complexes”, Budapest.

Hungary; Vol.12, p13. 1982.

240. Gandhi, R. B. and Karara, A. H., “Characterization, Dissolution and Diffusion Properties

of Tolbutamide-13-cyclodextrin Complex System”, Drug Dev. Ind. Pharm, 14:657.1988.

241. McCandless R, Yalkowsky SH. “Effect of hydroxypropyl-beta-cyclodextrin and pH on

the solubility of levemopamil HCl”, J. Pharm. Sci.; 87(12): 1639-42, 1998.

242. S.N. Luu, P.F. Carlier, P. Delort, J. Gazzola and D. Lafont, J. Pharm. Sci., 62, 452

(1973).

243. Khan, C.R. and Shechter, Y. and Goodman and Gilman’s; The Pharmacological basis

of Therapeutics, 8th

Edn., McGraw Hill, New York, 1712,1991.

244. S. Dhawan* and A.K. Singla., Performance Liquid Chromatographic Analysis of Glipizide:

Application to In Vitro and In Vivo Studies, J. Chromatogr. Sci., 2003, 41(6), 295-300.